Akoya Biosciences Current Ratio 2020-2021 | AKYA

Akoya Biosciences current ratio from 2020 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Akoya Biosciences Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.16B $0.02B 8.67
2021-03-31 $0.02B $0.02B 1.17
2020-12-31 $0.03B $0.02B 1.67
2020-06-30 $0.00B 0.00
2020-03-31 $0.00B 0.00
2019-12-31 $0.04B $0.02B 1.93
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.584B $0.042B
Akoya Biosciences Inc. offers comprehensive single-cell imaging solutions which allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. The company offer distinct solutions, the CODEX(R) and Phenoptics(TM) platforms, to serve the diverse needs of researchers across discovery, translational and clinical research. Akoya Biosciences Inc. is based in MARLBOROUGH, Mass.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29